CZEN 002

Drug Profile

CZEN 002

Alternative Names: (CKPV)2; MSH 11-13 Dimer

Latest Information Update: 09 Sep 2010

Price : $50

At a glance

  • Originator Zengen
  • Developer Abiogen Pharma
  • Class Antifungals; Melanocyte-stimulating hormones; Peptides
  • Mechanism of Action Alpha-MSH stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Mycoses; Ophthalmic infections; Periodontal disorders; Vulvovaginal candidiasis

Most Recent Events

  • 22 Jun 2005 Clinical trials in Mycoses in USA (Intradermal)
  • 22 Jun 2005 Phase-II clinical trials in Vulvovaginal candidiasis in Canada (Vaginal)
  • 22 Jun 2005 Phase-II clinical trials in Vulvovaginal candidiasis in European Union (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top